Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 479 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Manifestations Clear all
Completed Phase 3 Interventional

Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer

NCT00090337
View directory record Official record
Conditions
Head and Neck Cancer, Pain
Interventions
acupuncture therapy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers

NCT00743119
View directory record Official record
Conditions
Pain Threshold, Mood
Interventions
Placebo capsules, Inactive marijuana (0% THC), Low dose Dronabinol, High dose Dronabinol, Low THC marijuana, High THC marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Oral Midazolam in First-trimester Surgical Abortions

NCT01830881
View directory record Official record
Conditions
Pain, Anxiety, Nausea
Interventions
Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 14, 2026, 8:27 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking

NCT02849587
View directory record Official record
Conditions
Cannabis Intoxication
Interventions
Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 55 Years
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475
View directory record Official record
Conditions
Endometriosis
Interventions
Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Olanzapine for Acute Headaches

NCT03066622
View directory record Official record
Conditions
Headache
Interventions
Standard of Care as per attending physician, 5mg rapidly dissolving olanzapine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 14, 2026, 8:27 AM EDT
Withdrawn Phase 2 Interventional

Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

NCT03384095
View directory record Official record
Conditions
Breast Neoplasm Female, Arthralgia
Interventions
Hyaluronic Acid (HA), Placebo
Drug · Other
Lead sponsor
Erin Newton
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

NCT04056195
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
SKI-O-703, Placebo oral tablet
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 14, 2026, 8:27 AM EDT
Withdrawn No phase listed Observational

Disposable Endoscope Platform in Third Space Endoscopic Procedures

NCT06738628
View directory record Official record
Conditions
Achalasia, Gastroparesis
Interventions
(Esophageal or Gastric) Per-Oral Endoscopic Myotomy
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

NCT00522275
View directory record Official record
Conditions
Partial Epilepsies
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 14, 2026, 8:27 AM EDT
Withdrawn Phase 4 Interventional

Prophylactic Analgesia for Bladder Botox Injections

NCT06514430
View directory record Official record
Conditions
Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
Interventions
Phenazopyridine, 1% lidocaine with sodium bicarbonate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 14, 2026, 8:27 AM EDT
Not yet recruiting Phase 4 Interventional

Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain

NCT07595302
View directory record Official record
Conditions
Pelvic Pain
Interventions
Acetaminophen 1000mg PO, IV Acetaminophen 1000mg, IV Placebo, PO Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

NCT00663767
View directory record Official record
Conditions
Dental Pain
Interventions
Placebo; oral, ARRY-371797, p38 inhibitor; oral, Celecoxib, COX-2 inhibitor; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 14, 2026, 8:27 AM EDT
Completed No phase listed Observational

Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic

NCT00533884
View directory record Official record
Conditions
Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Interventions
Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

NCT01552863
View directory record Official record
Conditions
Pain
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Bilateral Sagittal Split Osteotomy Induced Paresthesia Using Ultrasonic vs. Reciprocating Saw Instrumentation

NCT05205616
View directory record Official record
Conditions
Surgical Complication, Paresthesia, Fracture, Nerve Injury, Nerve Entrapments, Mandibular Nerve Injuries, Mandibular Hypoplasia, Mandibular Retrognathism, Mandibular Hyperplasia, Mandibular Prognathism
Interventions
Sonopet ultrasonic saw, Reciprocating saw
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

NCT07123584
View directory record Official record
Conditions
Dry Eye, Eye Fatigue
Interventions
Eye Empower, Placebo
Dietary Supplement
Lead sponsor
Bio Nature Health
Industry
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 14, 2026, 8:27 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984
View directory record Official record
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 8:27 AM EDT
Completed No phase listed Observational

Journey of Patients With Vasculitis From First Symptom to Diagnosis

NCT03410290
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions
Online Questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 14, 2026, 8:27 AM EDT
Recruiting Phase 1 Interventional

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417
View directory record Official record
Conditions
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions
RAY121
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01727713
View directory record Official record
Conditions
Tourette's Disorder, Tic Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Dothan, Alabama • Goodyear, Arizona • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 14, 2026, 8:27 AM EDT